- Revolution Medicines (NASDAQ:RVMD) on Wednesday announced that it has commenced an underwritten public offering to sell up to $300 million of shares of its common stock.
- All of the shares of common stock are being offered by Revolution Medicines.
- The company also intends to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of common stock.
- The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- J.P. Morgan, TD Cowen, SVB Securities and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
- UBS Investment Bank is acting as lead manager for the proposed offering.
- Press Release.
- Shares -6.8% at $24.70 by 6:49 pm ET.